Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorAssiut University

About this trial

Osteoarthritis (OA) and sarcopenia are two highly prevalent, interconnected geriatric syndromes that often coexist, leading to a condition termed "osteosarcopenia". Globally, the pooled prevalence of sarcopenia in patients with knee OA is estimated at approximately 25.07%, significantly higher than in the general population.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults aged 40 years and older diagnosed with knee OA based on the American College of Rheumatology (ACR) criteria.

Patients who are willing to participate and provide informed written consent.

Disqualifiers

Inflammatory arthritis: patients with rheumatoid arthritis, gouty arthritis, or systemic lupus erythematosus (SLE) to avoid confusion with inflammatory muscle wasting.

Physical Limitations: amputees or those with severe physical deformities preventing gait speed tests or handgrip measurement.

Patients with cardiac pacemakers or implanted electronic devices (as these interfere with Bioelectrical Impedance Analysis (BIA)).

Severe Comorbidities: end-stage renal or hepatic disease, advanced malignancy or cachexia.

Trial population

Adult patients aged 40 years and older, diagnosed with knee osteoarthritis, who are attending the Assiut University Trauma Hospital.

Trial design

Design model

Other

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

224 Participants
are grouped into 1 trial group
Group A: Knee Osteoarthritis Patients

Trial outcomes

Primary outcomes

1

Prevalence of sarcopenia in knee osteoarthritis patients

Prevalence of OA patients who meet the diagnostic criteria for sarcopenia (low muscle mass, strength, and physical performance) according to the European Working Group on Sarcopenia in Older People (EWGSOP2) revised consensus.

Time frame
at baseline

Secondary outcomes

1

Nutritional Risk Assessment via Malnutrition Universal Screening Tool (MUST)

Evaluation of nutritional status as a factor associated with sarcopenia. The MUST score is a five-step screening tool with a total score ranging from 0 (low risk) to 2 or more (high risk).

Time frame
Baseline
2

The Quality of Life Factor (EQ-5D Index)

Assessment of the impact of sarcopenia and OA on quality of life. The 5 dimensions (Mobility, Self-care, Usual activities, Pain/discomfort, Anxiety/depression)

Time frame
Baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: